Renaissance Technologies LLC Has $69,000 Stock Holdings in Aileron Therapeutics, Inc. (NASDAQ:ALRN)

Renaissance Technologies LLC trimmed its position in Aileron Therapeutics, Inc. (NASDAQ:ALRN) by 44.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,864 shares of the company’s stock after selling 20,200 shares during the period. Renaissance Technologies LLC owned approximately 0.12% of Aileron Therapeutics worth $69,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Warberg Asset Management LLC acquired a new stake in Aileron Therapeutics during the 2nd quarter worth approximately $86,000. Texas Capital Bank Wealth Management Services Inc raised its holdings in shares of Aileron Therapeutics by 65.9% in the first quarter. Texas Capital Bank Wealth Management Services Inc now owns 26,171 shares of the company’s stock valued at $174,000 after purchasing an additional 10,398 shares during the last quarter. Finally, University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Aileron Therapeutics in the second quarter valued at approximately $4,925,000. 90.89% of the stock is currently owned by institutional investors and hedge funds.

Aileron Therapeutics Stock Down 0.8 %

NASDAQ ALRN opened at $3.59 on Tuesday. Aileron Therapeutics, Inc. has a 12-month low of $1.01 and a 12-month high of $7.42. The company has a market capitalization of $77.60 million, a PE ratio of -1.13 and a beta of 2.35. The firm’s 50 day moving average is $2.81 and its 200-day moving average is $3.40.

Aileron Therapeutics (NASDAQ:ALRN) last released its earnings results on Wednesday, August 14th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.20). As a group, sell-side analysts expect that Aileron Therapeutics, Inc. will post -1.41 EPS for the current year.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).